2 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2 / Phase 3 | Unknown | Kartos Therapeutics, Inc. | 385 | 2019-01-15 | 2023-04-28 |
| Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer | Phase 3 | Unknown | University of Glasgow | 214 | 2009-04-01 | 2011-05-13 |
Anxiety Disorders (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Depression (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Immunoglobulin Light-chain Amyloidosis (1) · Intraocular Lymphoma (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Mast-Cell (1)
Bone Marrow Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Amyloidosis (1) · Behavior (1) · Behavioral Symptoms (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Bone Marrow Neoplasms (1) · Carcinogenesis (1) · Cardiovascular Diseases (1) · Cell Transformation, Neoplastic (1) · Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Ketamine (1) · Pharmacogenomic Testing (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)
Kartos Therapeutics, Inc. (1) · University of Glasgow (1)
United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Israel (1) · Italy (1)
Barry J.A. Laird, MD (1) · Marie T. Fallon (1)